Kevin L Ong1, Maria Runa1, Edmund Lau2, Roy Altman3. 1. Exponent, Inc., Philadelphia, PA, USA. 2. Exponent, Inc., Menlo Park, CA, USA. 3. Academic Speakers of America, Agua Dulce, CA, USA.
Abstract
OBJECTIVE: There is debate about the effectiveness of intra-articular (IA) hyaluronic acid (HA) injections. We asked the following questions: (1) What is the epidemiology of IA HA use in knee arthroplasty (KA) patients? (2) Is Synvisc associated with a delay to KA? (3) Is there a difference in the delay to KA with the number of HA courses? DESIGN: The Optum Clinformatics data set (2006-June 2016) was used to identify patients with knee osteoarthritis (OA). Patients who did not receive IA HA were identified, along with those who received Synvisc or non-Synvisc HA. The median duration from knee OA to KA was compared using quantile regression modeling with propensity score weighting. The trend in time to KA with each HA course was evaluated. RESULTS: Of 4,027,848 knee OA patients, 141,305 patients underwent KA. Overall median time from knee OA diagnosis to KA was 1.2 years (average: 1.9 ± 1.9 years; interquartile range of 0.4-2.8 years). HA patients had significantly longer adjusted median time to KA by at least 7 months (P < 0.001). After adjusting for the time to HA and number of injections, Synvisc patients had 1.7 months longer time to KA than non-Synvisc HA patients (P < 0.001). There was a trend toward longer time to KA with more HA courses. CONCLUSIONS: Most KA patients did not use HA (73.7%) and when received, it was associated with a longer median time to KA by at least 7 months, though the cause and effect could not be examined. The delay to KA increased with more HA courses.
OBJECTIVE: There is debate about the effectiveness of intra-articular (IA) hyaluronic acid (HA) injections. We asked the following questions: (1) What is the epidemiology of IA HA use in knee arthroplasty (KA) patients? (2) Is Synvisc associated with a delay to KA? (3) Is there a difference in the delay to KA with the number of HA courses? DESIGN: The Optum Clinformatics data set (2006-June 2016) was used to identify patients with knee osteoarthritis (OA). Patients who did not receive IA HA were identified, along with those who received Synvisc or non-Synvisc HA. The median duration from knee OA to KA was compared using quantile regression modeling with propensity score weighting. The trend in time to KA with each HA course was evaluated. RESULTS: Of 4,027,848 knee OA patients, 141,305 patients underwent KA. Overall median time from knee OA diagnosis to KA was 1.2 years (average: 1.9 ± 1.9 years; interquartile range of 0.4-2.8 years). HApatients had significantly longer adjusted median time to KA by at least 7 months (P < 0.001). After adjusting for the time to HA and number of injections, Synvisc patients had 1.7 months longer time to KA than non-Synvisc HApatients (P < 0.001). There was a trend toward longer time to KA with more HA courses. CONCLUSIONS: Most KA patients did not use HA (73.7%) and when received, it was associated with a longer median time to KA by at least 7 months, though the cause and effect could not be examined. The delay to KA increased with more HA courses.
Authors: Marc C Hochberg; Roy D Altman; Karine Toupin April; Maria Benkhalti; Gordon Guyatt; Jessie McGowan; Tanveer Towheed; Vivian Welch; George Wells; Peter Tugwell Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Steven M Kurtz; Kevin L Ong; Edmund Lau; Marcel Widmer; Milka Maravic; Enrique Gómez-Barrena; Maria de Fátima de Pina; Valerio Manno; Marina Torre; William L Walter; Richard de Steiger; Rudolph G T Geesink; Mikko Peltola; Christoph Röder Journal: Int Orthop Date: 2011-03-15 Impact factor: 3.075
Authors: Raveendhara R Bannuru; Christopher H Schmid; David M Kent; Elizaveta E Vaysbrot; John B Wong; Timothy E McAlindon Journal: Ann Intern Med Date: 2015-01-06 Impact factor: 25.391
Authors: Job Hermans; Marc A Koopmanschap; Sita M A Bierma-Zeinstra; Joost H van Linge; Jan A N Verhaar; Max Reijman; Alex Burdorf Journal: Arthritis Care Res (Hoboken) Date: 2012-01-19 Impact factor: 4.794
Authors: T E McAlindon; R R Bannuru; M C Sullivan; N K Arden; F Berenbaum; S M Bierma-Zeinstra; G A Hawker; Y Henrotin; D J Hunter; H Kawaguchi; K Kwoh; S Lohmander; F Rannou; E M Roos; M Underwood Journal: Osteoarthritis Cartilage Date: 2014-01-24 Impact factor: 6.576
Authors: A A Guccione; D T Felson; J J Anderson; J M Anthony; Y Zhang; P W Wilson; M Kelly-Hayes; P A Wolf; B E Kreger; W B Kannel Journal: Am J Public Health Date: 1994-03 Impact factor: 9.308
Authors: Francis Berenbaum; Joachim Grifka; Sara Cazzaniga; Massimo D'Amato; Giampaolo Giacovelli; Xavier Chevalier; Francois Rannou; Lucio C Rovati; Emmanuel Maheu Journal: Ann Rheum Dis Date: 2012-01-31 Impact factor: 19.103
Authors: Gerard Malanga; Faizan Niazi; Vasco Deon Kidd; Edmund Lau; Steven M Kurtz; Kevin L Ong; Andrew L Concoff Journal: Am Health Drug Benefits Date: 2020-09
Authors: Angelo Boffa; Luca Andriolo; Marco Franceschini; Alessandro Di Martino; Emanuela Asunis; Alberto Grassi; Stefano Zaffagnini; Giuseppe Filardo Journal: Orthop J Sports Med Date: 2021-10-05